Using high precision climate data for wildfire risk assessment

The present study is focused on examining the changes of key weather parameters using detailed daily data for the period 1985-2021 in an area of interest situated in Rila mountain in Bulgaria which is a territory that is prone to wildfires. Using this long-term horizon, the research defines the main climate factor trends and relates them with real events of wildfires by using the Angström index and statistical methods with focus on outlining specific weather conditions that indicate fire risk. As a result, the Angström index was proven to be a reliable source for determining the potential weather conditions for fire occurrence in the area of interest, part of protected area BG0000496 Rilski manastir. Low relative humidity was identified as the main factor influencing fire occurrence in the reviewed real wildfire events. Specific range and behavior of the key weather parameters, influencing wildfire occurrence were detected. These findings could be a good source of information when elaborating a forest fire prevention system and may help for appropriate prioritization of factors and management of resources

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation